Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Beumont

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
BMC Public Health|February 26, 2024
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United StatesMondher Toumi, Jack Wallace, Chari Cohen, et al.
Nature Reviews. Gastroenterology & Hepatology|July 20, 2022
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlookAnna Kramvis, Kyong-Mi Chang, Maura Dandri, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Journal of Hepatology|October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infectionStefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
BMC Public Health|February 26, 2024
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United StatesMondher Toumi, Jack Wallace, Chari Cohen, et al.
Nature Reviews. Gastroenterology & Hepatology|July 20, 2022
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlookAnna Kramvis, Kyong-Mi Chang, Maura Dandri, et al.
Pageof 5